CapsoVision (NASDAQ:CV) Reaches New 12-Month High – Should You Buy?

by · The Cerbat Gem

Shares of CapsoVision, Inc. (NASDAQ:CV – Get Free Report) reached a new 52-week high on Wednesday . The company traded as high as $11.80 and last traded at $11.80, with a volume of 187085 shares. The stock had previously closed at $8.89.

Analyst Upgrades and Downgrades

CV has been the topic of several recent research reports. Zacks Research upgraded shares of CapsoVision to a “hold” rating in a research report on Wednesday, November 5th. Roth Capital set a $7.00 price target on CapsoVision in a report on Tuesday, November 4th. Weiss Ratings reissued a “sell (e)” rating on shares of CapsoVision in a report on Monday. Finally, Benchmark reaffirmed a “speculative buy” rating on shares of CapsoVision in a research note on Friday, November 14th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $6.00.

Get Our Latest Report on CV

CapsoVision Stock Performance

The company’s fifty day moving average is $5.71.

CapsoVision (NASDAQ:CV – Get Free Report) last announced its earnings results on Thursday, November 13th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The company had revenue of $3.54 million during the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in CapsoVision stock. Citadel Advisors LLC purchased a new position in CapsoVision, Inc. (NASDAQ:CV – Free Report) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 23,735 shares of the company’s stock, valued at approximately $115,000. Citadel Advisors LLC owned approximately 0.05% of CapsoVision at the end of the most recent quarter.

CapsoVision Company Profile

(Get Free Report)

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn’s disease.

Featured Stories